UK's Crackdown On Anti-Competitive Deals Continues; Actavis In Firing Line Again
Executive Summary
The UK's competition authority is keen to expose supposed pay-for-delay deals made by pharmaceutical firms, and is warning drug suppliers to think twice before attempting agreements that slow the entry of generic products onto the UK market.
You may also be interested in...
UK Competition Regulator Steps Up Hydrocortisone Probe
Two generics firms have been provisionally found to have breached competition law by reaching agreements intended to delay the entry of competing products.
UK Competition Body Steps Up Generic Hydrocortisone Probe
Two generics firms have been provisionally found to have breached competition law by reaching agreements intended to delay the entry of competing products.
Concordia Names Six Drugs Targeted By UK Competition Inquiry
Concordia has announced that six more of its medicines are involved in the UK competition inquiry. One law firm says the announcement further underlines the Competition and Markets Authority’s determination to root out anticompetitive practices in the pharma area.